GlassScriptPhysician profile
Yurhee Lee
NPI 1457887606
$2,112.32
in general payments reported to CMS, 2019-2025
28 companies · $407 in 2025
The $407 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $39.37 · 2022: $333 · 2023: $624 · 2024: $710 · 2025: $407.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,578 · Education: $162.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,578.41 |
| Education | $161.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $310.05 | 2023-2024 | Vyloy, Xospata |
| Celgene Corporation | $195.22 | 2021-2023 | Reblozyl, Pomalyst |
| Genzyme Corporation | $188.64 | 2023-2024 | |
| Amgen INC. | $181.98 | 2022 | |
| Gt Medical Technologies, INC | $151.16 | 2025 | Gammatile |
| Seagen INC. | $119.87 | 2022-2023 | Adcetris |
| Tempus Ai, INC | $115.61 | 2024 | |
| Sumitomo Pharma America, INC. | $105.58 | 2024 | Orgovyx |
| Incyte Corporation | $102.50 | 2023-2024 | Jakafi, Pemazyre, Monjuvi |
| Astrazeneca Pharmaceuticals LP | $76.34 | 2023-2025 | Enhertu, Imfinzi |
| Adc Therapeutics America, INC. | $58.83 | 2023-2024 | |
| Genentech USA, INC. | $55.71 | 2024-2025 | Tecentriq |
| Abbvie INC. | $50.33 | 2024-2025 | |
| Alexion Pharmaceuticals, INC. | $42.97 | 2024 | Ultomiris |
| Daiichi Sankyo INC. | $40.76 | 2025 | Enhertu, Datroway |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Karyopharm Therapeutics INC. | $33.62 | 2023 | Xpovio |
| Geron Corporation | $31.38 | 2025 | Rytelo |
| Immunogen, INC. | $29.21 | 2023 | Elahere |
| Tersera Therapeutics LLC | $28.70 | 2023 | Xermelo |
| Alnylam Pharmaceuticals INC. | $27.84 | 2025 | Givlaari |
| Lilly USA, LLC | $26.45 | 2025 | Verzenio, Jaypirca |
| Merck Sharp & Dohme LLC | $25.84 | 2025 | Keytruda |
| Bayer Healthcare Pharmaceuticals INC. | $21.98 | 2024 | |
| Pfizer INC. | $21.41 | 2024 | |
| Mirati Therapeutics, INC. | $19.96 | 2023 | Krazati |
| Foundation Medicine, INC. | $18.52 | 2023 | |
| Agios Pharmaceuticals, INC. | $16.09 | 2025 | Pyrukynd |
| E.R. Squibb & Sons, L.L.C. | $15.77 | 2025 | Opdivo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yurhee Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.